Table 2 Comprehensive analysis of cancer risk in raltegravir trials.
Raltegravir | Comparator | Relative Risk | |||
|---|---|---|---|---|---|
Cases/Year at Risk | Cases/Year at Risk | ||||
N | N | (95% CI) | |||
(Rate) | (Rate) | ||||
Overall | 1039 | 29/1722 | 605 | 17/159 | 0.75 |
(1.68) | (2.24) | (0.40-1.46) | |||
Treatment experienced patients | |||||
Protocol 005 | 133 | 0/100 (0.00) | 45 | 0/23 (0.00) | |
BENCHMRK-1 | 232 | 12/417 (2.88) | 118 | 2/133 (1.50) | |
BENCHMRK-2 | 230 | 12/384 (3.12) | 199 | 5/131 (3.81) | |
Treatment naïve patients | |||||
PROTOCOL 004 | 163 | 4/429 (0.93) | 41 | 1/100 (1.00) | |
STARTMRK | 281 | 1/392 (0.26) | 282 | 9/371 (2.42) | |